Prosecution Insights
Prosecution Insights
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| §112 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.6% | +32.4% |
| VU, JAKE MINH | 1 | 40.6% | +27.4% |
| LAZARO, DOMINIC | 1 | 63.3% | +30.8% |
| HILL, MYRON G | 1 | 66.3% | +20.1% |
| POPA, ILEANA | 1 | 21.5% | +14.6% |
| KELLY, ROBERT M | 1 | 73.7% | +24.8% |
| JOHNSON, ALLISON MARIE | 1 | 44.7% | +50.2% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 39.3% | +70.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913477 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FACTOR IX THERAPEUTICS | JOHNSON, ALLISON MARIE | 23d overdue |
| 18289622 | NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY | HILL, MYRON G | 4d overdue |
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | — |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19063950 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | VU, JAKE MINH | 73d overdue |
| 17430341 | MODULATION OF REP PROTEIN ACTIVITY IN CLOSED-ENDED DNA (CEDNA) PRODUCTION | LIPPOLIS, ALEXANDRA ROSE | 31d overdue |
| 17913477 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FACTOR IX THERAPEUTICS | JOHNSON, ALLISON MARIE | 23d overdue |
| 17913482 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING GAUCHER THERAPEUTICS | KELLY, ROBERT M | 16d overdue |
| 18289622 | NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY | HILL, MYRON G | 4d overdue |
| 19238030 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | CABRAL, ROBERT S | — |
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | — |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1614 | 1 |
| 1618 | 1 |
| 1671 | 1 |
| 1633 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19238030 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | CABRAL, ROBERT S | 1614 | §112 | Final Rejection | — | Pending | Jun 13, 2025 |
| 19063950 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | VU, JAKE MINH | 1618 | DP | Final Rejection | 73d overdue | Pending | Feb 26, 2025 |
| 18578073 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LAZARO, DOMINIC | — | §103§112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18289622 | NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY | HILL, MYRON G | 1671 | §102§103§112 | Non-Final OA | 4d overdue | Pending | Nov 06, 2023 |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Nov 15, 2022 |
| 17913482 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING GAUCHER THERAPEUTICS | KELLY, ROBERT M | 1638 | §103 | Non-Final OA | 16d overdue | Pending | Sep 22, 2022 |
| 17913477 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FACTOR IX THERAPEUTICS | JOHNSON, ALLISON MARIE | 1638 | §102§112Other | Non-Final OA | 23d overdue | Pending | Sep 22, 2022 |
| 17430341 | MODULATION OF REP PROTEIN ACTIVITY IN CLOSED-ENDED DNA (CEDNA) PRODUCTION | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 31d overdue | Pending | Aug 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial